Clinical trial · Interventional
Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma
Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Newly Diagnosed MGMT Promotor Unmethylated Glioblastoma
NCT05694416CI-TRIAL-00063376unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| MGMT-Unmethylated Glioblastoma | MGMT-Unmethylated Glioblastoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Etoposide Plus Cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Etoposide Plus Cisplatin group
- description
- Etoposide 100mg/m2 d1-5 Cisplatin 20mg/mCisplatin d1-5
- interventionNames
- Drug: Etoposide Plus Cisplatin
- type
- NO_INTERVENTION
- label
- Temozolomide group
- description
- Temozolomide 150-200mg/m2 d1-5
Primary outcomes (1)
- measure
- OVER SURVIVAL
- timeFrame
- 2 YEARS
- description
- The length of time from the date of diagnosis to death from cancer
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 18 and 70, * performance status of 0-1 (Eastern Cooperative Oncology Group performance status), * histologically confirmed MGMT gene promoter unmethylation glioblastoma * no cerebrospinal fluid and distant metastatic disease. * adequate hematologic, hepatic, and renal function Exclusion Criteria: * younger than 18 years; * with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities
References
Publications (0)
Data not yet available
No reference posted for this study.